AbbVie rises as 3rd-qtr earnings beat estimates

28 October 2017
abbvie-logo-big

Shares of USA-based AbbVie (NYSE: ABBV) closed up 2.33% at $91.93 on Friday, having hit a day high of $94.97, after the company post third-quarter 2017 financial results.

AbbVie posted revenues of $7 billion, a year-on-year rise of 8.8% and in line with the Zacks Equity Research and consensus Wall Street estimates.

The company’s net earnings rose 2.1% to $1.63 billion in the third quarter. AbbVie's third-quarter earnings came in at $1.41 per share, beating the Zacks consensus estimate of $1.39.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical